Skip to main content

COVID-19 Topic Center

Diabetes Expert Insights

Pharmacy Learning Network
By Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS  Volume3, Issue 1 “Pour some sugar on me” SGLT2 inhibitors have morphed into somewhat of a pharmacologic panacea over the last half-decade. First, there was the serendipitous discovery of cardio-protective effects in patients with…
Pharmacy Learning Network
Diabetes is a well-known risk factor for the development of heart failure.1 Pre-diabetes continues to grow in the United States.2 This is important because pre-diabetes associated dysglycemia is associated with abnormal cardiac structure and function, associated with a higher risk of heart failure.…
Pharmacy Learning Network
By Yvette C. Terrie, BS Pharm, RPh, Consultant Pharmacist Metformin is one of the most extensively prescribed drugs used to treat T2DM and is also recommended by the American Diabetes Association (ADA) as the preferred initial pharmacological agent for the treatment of T2DM either alone or in…
Pharmacy Learning Network
By: Yvette C. Terrie, RPh, BS Pharm, Consultant Pharmacist, Medical Writer As frontline health care providers, pharmacists are in a pivotal position to act as patient identifiers, patient educators and patient advocates especially for those at risk for or with diabetes. They can also utilize…
Pharmacy Learning Network
By Julie Gould  Researchers recently found that use of glucagon-like peptide-1 (GLP-1) receptor agonists positively impacted glycemic control, weight, and reduced polytherapy, however, “the increase in monthly glucose-lowering medication cost was significant and may serve as a barrier to treatment…
Pharmacy Learning Network
By Julie Gould Julie Lauffenburger, PharmD, Harvard Medical School and division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital, explains how more intensive insulin-adherence interventions impact patient outcomes and highlights the challenges faced when…
Back to Top